Johnson & Johnson (NYSE:JNJ) Coverage Initiated at TD Cowen

Analysts at TD Cowen started coverage on shares of Johnson & Johnson (NYSE:JNJ) in a note issued to investors on Wednesday. The firm set a “buy” rating and a $250.00 price target on the stock. TD Cowen’s price objective would indicate a potential upside of 5.28% from the company’s previous close.

Several other research analysts also recently weighed in on JNJ. Freedom Capital downgraded shares of Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research report on Friday, January 16th. Wells Fargo & Company raised their price objective on shares of Johnson & Johnson from $230.00 to $240.00 and gave the stock an “overweight” rating in a research note on Thursday, January 22nd. Rothschild & Co Redburn boosted their target price on shares of Johnson & Johnson from $180.00 to $210.00 and gave the company a “neutral” rating in a research note on Thursday, February 19th. Scotiabank restated an “outperform” rating on shares of Johnson & Johnson in a report on Thursday, January 22nd. Finally, Morgan Stanley set a $253.00 target price on Johnson & Johnson in a research report on Wednesday, March 18th. One analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and nine have issued a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $237.57.

Johnson & Johnson Price Performance

Johnson & Johnson stock traded down $0.94 during mid-day trading on Wednesday, hitting $237.47. The company’s stock had a trading volume of 611,116 shares, compared to its average volume of 8,590,287. The stock has a market capitalization of $571.96 billion, a P/E ratio of 21.35, a P/E/G ratio of 2.41 and a beta of 0.34. Johnson & Johnson has a twelve month low of $141.50 and a twelve month high of $251.71. The stock’s fifty day moving average price is $240.53 and its two-hundred day moving average price is $214.17. The company has a quick ratio of 0.77, a current ratio of 1.03 and a debt-to-equity ratio of 0.48.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Saturday, January 31st. The company reported $2.46 earnings per share for the quarter. The business had revenue of $24.28 billion during the quarter. Johnson & Johnson had a return on equity of 33.04% and a net margin of 28.46%. Research analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current year.

Insider Activity at Johnson & Johnson

In other Johnson & Johnson news, EVP Vanessa Broadhurst sold 6,197 shares of the stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $243.39, for a total value of $1,508,287.83. Following the completion of the sale, the executive vice president owned 23,003 shares in the company, valued at $5,598,700.17. This represents a 21.22% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Timothy Schmid sold 22,623 shares of Johnson & Johnson stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $244.33, for a total transaction of $5,527,477.59. Following the sale, the executive vice president directly owned 26,769 shares of the company’s stock, valued at $6,540,469.77. This trade represents a 45.80% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 30,142 shares of company stock worth $7,360,528. Company insiders own 0.16% of the company’s stock.

Institutional Investors Weigh In On Johnson & Johnson

A number of hedge funds and other institutional investors have recently made changes to their positions in JNJ. Auto Owners Insurance Co raised its position in Johnson & Johnson by 22,225.6% during the fourth quarter. Auto Owners Insurance Co now owns 69,419,308 shares of the company’s stock valued at $1,436,633,000 after acquiring an additional 69,108,368 shares in the last quarter. Norges Bank bought a new stake in Johnson & Johnson in the fourth quarter worth approximately $6,924,523,000. Capital World Investors acquired a new position in shares of Johnson & Johnson during the 4th quarter worth $2,005,942,000. Vanguard Group Inc. raised its holdings in shares of Johnson & Johnson by 1.6% during the 4th quarter. Vanguard Group Inc. now owns 240,349,660 shares of the company’s stock valued at $49,740,362,000 after purchasing an additional 3,731,074 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD raised its holdings in shares of Johnson & Johnson by 41.7% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 12,423,886 shares of the company’s stock valued at $2,571,124,000 after purchasing an additional 3,655,754 shares in the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.

Johnson & Johnson News Summary

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Citi raised its price target to $285 and kept a Buy rating, signaling sizable upside from current levels which is drawing buying interest. Citigroup Raises PT to $285
• Positive Sentiment: Guggenheim nudged its target to $244 and kept a Buy rating — another analyst endorsement supporting demand for the shares. Guggenheim Raises PT to $244
• Positive Sentiment: TD Cowen reiterated a Buy with a $250 target, adding to the analyst support narrative that’s boosting sentiment. TD Cowen Buy Rating
• Positive Sentiment: Product/pipeline progress: J&J received CE mark and launched Varipulse Pro in Europe (next‑gen PFA catheter with faster ablation), and reported specialty therapy updates including a permanent US reimbursement code for INLEXZO and positive ICOTYDE data — these are concrete near‑term commercial catalysts. Varipulse Pro Launch
• Neutral Sentiment: Market commentary and stock‑selection pieces are highlighting J&J as a low‑volatility, dividend‑growth blue chip and a name “near buy zone,” which tends to support steady demand from income and momentum investors. Low‑Volatility Blue Chip Coverage
• Neutral Sentiment: Aggregated analyst‑call roundups and consensus ratings (e.g., “Moderate Buy”) keep JNJ on investors’ radar but don’t change fundamentals immediately. Analyst Research Calls Roundup
• Negative Sentiment: Not all upgrades imply big near‑term upside — Guggenheim’s new $244 target implies only a small premium to current levels, highlighting that some analyst moves are modest and valuation could limit immediate gains. Guggenheim PT Context

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.